Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson B, Dahl O, Rosencher N, Kurth A, et al. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson B, Dahl O, Rosencher N, Kurth A, et al.
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Development of a neuroprotective drug could potentially reduce disability from stroke by 50%.  
  • According to the Pharmaceutical Research and Manufacturers of America, 146 new medicines are being developed for heart disease and stroke. They include 17 for stroke, 16 for congestive heart failure,…  
  • Every additional dollar spent on the overall treatment of stroke has produced health gains valued at $1.55.  
  • Development and widespread use of left ventricular assist devices could result in a 50% decrease in heart failure-related hospitalizations.  
  • If all forms of cardiovascular disease were eliminated, life expectancy would rise by close to 7 years.